We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Cn5.0
Carnosine Research
Likely helps
70 peer-reviewed studies
What the evidence says
Likely helps
Carnosine appears to help in 6 of 8 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 1995–2026 with a typical study size of 88 participants.
Based on 70 studies · 17 meta-analyses · 39 RCTs · 11,686 total participants
Confidence
High confidence
What the studies found
6helped1unclear1didn't help· 62 more without graded effect data
By outcome
Therapeutic & clinical
Mostly mechanism / observational17 studies
Glucose & metabolicMeta-analyses show modest reductions in fasting glucose and HbA1c · 8-12 weeks
Mostly mechanism / observational14 studies
Cognitive function
Mostly mechanism / observational13 studies
InflammationRecent RCTs found no effect on inflammatory markers · 4-8 weeks
Mostly mechanism / observational8 studies
Endurance & exercise performanceBuffering benefit is mainly from the precursor beta-alanine, not carnosine · 2-4 weeks
Mostly mechanism / observational6 studies
Heart & blood pressure
Mostly mechanism / observational4 studies
Cholesterol & lipids
Mostly mechanism / observational3 studies
Muscle strength & power
Mostly mechanism / observational3 studies
Lean body mass & muscle growth
Mostly mechanism / observational3 studies
Safety profile
Mostly mechanism / observational3 studies
Pain & analgesia
Too few graded studies1 study
Vision & eye health
Too few graded studies1 study
By the numbers
Pulled from 27 studies with measurable effects
Likely real effects
100%
across studies
People studied
12k
typical study: 88 people
Strongest designs
56
17 pooled, 39 randomised
Showed benefit
75%
6/8 studies
How long studies ran
1–3 months
2
Populations Studied
General population3
Autism spectrum disorder patients2
Trained young male individuals1
Prediabetes and type 2 diabetes patients1
Active research area
31 studies in the last 5 years · Latest meta-analysis: 2025
199520102026
1Autism spectrum disorder core symptomsMeta-AnalysisCited 72×n=7,450 · very large study2022
Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms.
Siafis S et al. · Molecular autism (2022)
Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms.
Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended.
2Maximal intensity exercise performanceMeta-AnalysisCited 4×n=331 · medium study2024
A significant (p = .01) result was observed with an overall effect size of 0.39 (95% confidence interval [CI] [0.09, 0.69]), in favor of beta-alanine supplementation versus placebo.
Georgiou GD et al. · International Journal of Sport Nutrition and Exercise Metabolism (2024)
Noticeable benefit
← WorseNo effectBetter →
Likely real
A total of 18 individual studies were analyzed, employing 18 exercise test protocols and 15 outcome measures in 331 participants.
Significant effects at a high beta-alanine dosage of 5.6-6.4 g per day, effect size 0.35 (95% CI [0.09, 0.62], p = .009).
4-10 min of maximal effort showed effect size 0.55 (95% CI [0.07, 1.04], p = .03).
4Exercise capacity and performanceMeta-AnalysisCited 196×n=1,461 · large study2017
β-alanine had a significant overall effect while subgroup analyses revealed a number of modifying factors.
Saunders B et al. · British journal of sports medicine (2017)
Barely noticeable benefit
← WorseNo effectBetter →
Likely real
A significant overall effect size of 0.18 (95% CI 0.08 to 0.28) was shown.
Meta-regression demonstrated that exercise duration significantly (p=0.004) moderated effect sizes.
Subgroup analyses also identified the type of exercise as a significant (p=0.013) moderator of effect sizes within an exercise time frame of 0.5-10 min with greater effect sizes for exercise capacity (0.4998 (95% CI 0.246 to 0.753)) versus performance (0.1078 (95% CI -0.201 to 0.416)).
Carnosine/HCD supplementation may reduce inflammatory and oxidative stress biomarkers, and potentially modulate the cardiometabolic risks associated with chronic low-grade inflammation and lipid peroxidation.
Saadati S et al. · Nutrition reviews (2024)
Carnosine/HCD supplementation may reduce inflammatory and oxidative stress biomarkers, and potentially modulate the cardiometabolic risks associated with chronic low-grade inflammation and lipid peroxidation.
10Systematic ReviewCited 11×n=221 · medium study2023
According to the results of the studies reviewed, we would recommend β-A and SB co-supplementation during high intensity exercises lasting between 30 s and 10 min.
Gilsanz L et al. · Critical reviews in food science and nutrition (2023)
Nine studies including a total of 221 athletes were identified for review.
Athletes were supplemented with β-A and SB while they performed exercise tests to assess physical performance and buffer capacity.
Five of the nine studies indicated there was some additional improvement in buffering capacity and performance with co-supplementation, while one study concluded that the effect was comparable to the added effects of the individual supplements.
11Systematic ReviewCited 14×n=22 · very small study2024
Based on the review, we cannot recommend any supplement use for the management of CIPN, although further research into N-acetyl-cysteine, l-carnosine, crocin, and magnesium is warranted.
Frediani JK et al. · Pain practice : the official journal of World Institute of Pain (2024)
Based on the review, we cannot recommend any supplement use for the management of CIPN, although further research into N-acetyl-cysteine, l-carnosine, crocin, and magnesium is warranted.
Acetyl-l-carnitine was found to be likely ineffective or harmful.
HCD, supplementation improved scores on the Delayed recall examination, a neuropsychological test affected early in Alzheimer's disease.
Bell SM et al. · Nutrition reviews (2024)
HCD, supplementation improved scores on the Delayed recall examination, a neuropsychological test affected early in Alzheimer's disease.
Further studies are needed in people with early cognitive impairment with longer follow-up duration and standardization of carnosine doses to delineate the true effect.
Clinical studies were conducted to manage chemotherapy induced toxicities and there are no clinical studies available for its anti-cancer use, and the current evidence does not support its use in the treatment of cardiovascular disease.
Sureshkumar K et al. · Frontiers in bioscience (Landmark edition) (2023)
Clinical studies were conducted to manage chemotherapy induced toxicities and there are no clinical studies available for its anti-cancer use, and the current evidence does not support its use in the treatment of cardiovascular disease.
Understanding the mechanisms that regulate skeletal muscle mass will help in developing effective treatments for muscle weakness.
Baumert P et al. · Journal of cachexia, sarcopenia and muscle (2024)
Like the hypertrophy stimulation with IGF-1 in myotubes in vitro, the concentration of the dipeptide l-carnosine was decreased by 26.6% (P = 0.001) during skeletal muscle growth in vivo.
However, phosphorylated sugar (glucose-6-phosphate, fructose-6-phosphate or glucose-1-phosphate) decreased by 32.2% (P = 0.004) in the overloaded muscle in vivo while increasing in the IGF-1-stimulated myotubes in vitro.
We demonstrated that labelled carbon from [U-13C6]glucose is increasingly incorporated by ~13% (P = 0.001) into the non-essential amino acids in hypertrophying myotubes, which is accompanied by an increased depletion of media serine (P = 0.006).
15HbA1C reductionMeta-AnalysisCited 12×n=184 · medium study2020
Carnosine supplementation results in a decrease in HbA1C, but elicits no effect on HOMA-IR, Cholesterol, fasting blood sugar, TG and HDL-C.
Peng W et al. · Complementary therapies in medicine (2020)
Noticeable benefit
← WorseNo effectBetter →
Overall results from the random-effects model on included studies, with 184 participants, indicated that carnosine intervention reduced HbA1C levels in intervention vs control groups (WMD: -0.92 %, 95 % CI: -1.20, -0.63, I2:69 %).
Four studies, including a total of 183 participants, reported TG changes as an outcome measure variable, but combined results did not show significant reduction in this outcome (WMD: -14.46 mg/dl, 95 % CI: -29.11, 0.19, I2:94 %).
Carnosine supplementation results in a decrease in HbA1C, but elicits no effect on HOMA-IR, Cholesterol, fasting blood sugar, TG and HDL-C.
16Exercise performance improvementMeta-AnalysisCited 210×n=360 · medium study2012
The median effect of β-alanine supplementation is a 2.85% (-0.37 to 10.49%) improvement in the outcome of an exercise measure, when a median total of 179 g of β-alanine is supplemented.
Hobson RM et al. · Amino acids (2012)
No clear effect
← WorseNo effectBetter →
Likely real
BA improved (P=0.002) the outcome of exercise measures to a greater extent than Pla [median effect size (IQR): BA 0.374 (0.140-0.747), Pla 0.108 (-0.019 to 0.487)].
Some of that effect might be explained by the improvement (P=0.013) in exercise capacity with BA compared to Pla; no improvement was seen for exercise performance (P=0.204).
In line with the purported mechanisms for an ergogenic effect of β-alanine supplementation, exercise lasting 60-240 s was improved (P=0.001) in BA compared to Pla, as was exercise of >240 s (P=0.046).
Inferences were made on posterior samples generated by Hamiltonian Markov Chain Monte Carlo using 90% credible intervals (90% CrI) and calculated probabilities.
Matthews JJ et al. · Advances in nutrition (Bethesda, Md.) (2021)
Inferences were made on posterior samples generated by Hamiltonian Markov Chain Monte Carlo using 90% credible intervals (90% CrI) and calculated probabilities.
GRADE assessment showed our certainty in the effect estimate of each outcome to be moderate (human outcomes) or very low (rodent outcomes).
Supplementation with carnosine or β-alanine may reduce fasting glucose, HbA1c, and HOMA-IR in humans and rodents, and fasting insulin in humans; both compounds show potential as therapeutics to improve glycemic control and insulin resistance.
19Prevention of advanced glycation end products (AGEs) formationSystematic ReviewCited 62×n=36 · small study2018
The mechanism by which carnosine prevents the formation of AGEs needs further investigation.
Ghodsi R et al. · Amino acids (2018)
This included 19 in vitro studies, 15 animal studies and two human studies.
All but two of the studies indicated that carnosine can prevent the formation of AGEs.
The findings of this review indicating that carnosine has anti-glycating properties, and may hinder the formation of protein carbonyls and the cross-links induced by reduced sugars; however, there were few human studies.
Dolan E et al. · Advances in nutrition (Bethesda, Md.) (2019)
Huge harm
← WorseNo effectBetter →
Paraesthesia was the only reported side effect and had an estimated OR of 8.9 [95% credible interval (CrI): 2.2, 32.6] with supplementation relative to placebo.
Meta-analysis of human data showed no main effect of β-alanine supplementation on skeletal muscle taurine (ES: 0.156; 95% CrI: -0.38, 0.72) or histidine (ES: -0.15; 95% CrI: -0.64, 0.33) concentration.
A main effect of β-alanine supplementation on taurine concentration was reported for murine models, but only when the daily dose was ≥3% β-alanine in drinking water.